Publication date: Dec 08, 2025
Sepsis is heterogeneous, and the optimal strategy for tailoring immunotherapy is uncertain. To investigate whether precision immunotherapy guided by the presence of macrophage activation-like syndrome or sepsis-induced immunoparalysis improves organ dysfunction by day 9. A randomized, double-blind, double-dummy, placebo-controlled clinical trial conducted in 6 countries. Patients with sepsis, defined by Sepsis-3, were included if they had community-acquired or hospital-acquired pneumonia or ventilator-associated pneumonia or bacteremia and sepsis and had displayed either macrophage activation-like syndrome (blood ferritin >4420 ng/mL) or sepsis-induced immunoparalysis (blood ferritin ≤4420 ng/mL and
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Sepsis |
| disease | MESH | syndrome |
| disease | MESH | included |
| disease | MESH | pneumonia |
| disease | MESH | ventilator-associated pneumonia |
| disease | MESH | bacteremia |
Original Article
(Visited 2 times, 1 visits today)